Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals has announced that it will release its full-year financial results for the period ended 31 December 2025 on 20 February 2026 AEDT, followed by an investor webcast and conference call on the same day to brief shareholders and analysts. The scheduled results publication and accompanying investor event underscore the company’s ongoing efforts to engage global capital markets and provide transparency around its performance as it advances a growing portfolio of radiopharmaceutical products in oncology and rare diseases.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$20.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical technologies, with a focus on addressing significant unmet medical needs in oncology and rare diseases. Headquartered in Melbourne, Australia, the company operates internationally across the United States, United Kingdom, Brazil, Canada, Europe and Japan, and is dual-listed on the Australian Securities Exchange and the Nasdaq Global Select Market under the ticker TLX.
Average Trading Volume: 2,064,855
Technical Sentiment Signal: Sell
Current Market Cap: A$3.57B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.